University of Iowa
Iowa City, Iowa, 52242, United States
Location status: Recruiting
Location contact
Anna Reid-Stanhewicz, PhD
PRINCIPAL_INVESTIGATOR
Claire Goebel
CONTACT
Kelsey Schwartz, PhD
CONTACT
NCT Number: NCT06749418
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear.
The purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function.
In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.
Interested in participating?
Request Info18 year–45 year
Female
Interventional
Early Phase 1
Iowa City, Iowa, 52242, United States
Location status: Recruiting
Anna Reid-Stanhewicz, PhD
PRINCIPAL_INVESTIGATOR
Claire Goebel
CONTACT
Kelsey Schwartz, PhD
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.
Time frame: Day 3 (low-salt diet run in) and Day 10 (low-salt diet + high-salt supplement)
Cutaneous vascular vasodilator response (cutaneous conductance; %max) to local heating of the skin; intradermal microdialysis for the local delivery of eplerenone compared to control (Ringer's solution), followed by L-NAME infusion to quantify NO-dependent response
Time frame: Day 2, Day 9
The investigators will measure urine sodium to ensure differences in salt-take between low- and high-salt.
Time frame: Day 3, Day 10
The investigators will collect blood at the start of each experiment to determine differences in aldosterone concentrations between low- and high-salt.
Time frame: Day 3, Day 10
The investigators will collect blood at the start of each experiment to determine differences in circulating angiotensin II concentrations between low- and high-salt.
Time frame: Day 2, Day 9
The investigators will measure ambulatory blood pressure, assessed as mean arterial pressure calculated from measured systolic and diastolic pressures, responses to low- and high-salt.
Contact information is provided by the study sponsor or research team.
Anna Stanhewicz, PhD
Other
Role of the Mineralocorticoid Receptor in Microvascular Endothelial Dysfunction After Preeclampsia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07167862
Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases
Orange, California, United States
View Trial DetailsNCT07345845
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Iowa City, Iowa, United States
View Trial DetailsNCT06373367
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Long Beach, California, United States
View Trial DetailsNCT07728656
Cardiovascular Diseases, Female Urogenital Diseases and Pregnancy Complications
Osijek, Croatia
View Trial Details